MCID: SCK020
MIFTS: 22

Sickle Cell - Hemoglobin D Disease malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Sickle Cell - Hemoglobin D Disease

Aliases & Descriptions for Sickle Cell - Hemoglobin D Disease:

Name: Sickle Cell - Hemoglobin D Disease 50
Sickle Cell-Hemoglobin D Disease Syndrome 50 56 29
Hbsd Disease 50 56

Characteristics:

Orphanet epidemiological data:

56
sickle cell-hemoglobin d disease syndrome
Inheritance: Autosomal recessive; Age of onset: All ages;

Classifications:



External Ids:

Orphanet 56 ORPHA251370
UMLS via Orphanet 70 C0272084
ICD10 via Orphanet 34 D57.2

Summaries for Sickle Cell - Hemoglobin D Disease

MalaCards based summary : Sickle Cell - Hemoglobin D Disease, also known as sickle cell-hemoglobin d disease syndrome, is related to hemoglobin d disease and acute chest syndrome. An important gene associated with Sickle Cell - Hemoglobin D Disease is HBB (Hemoglobin Subunit Beta). The drugs Iron and Hydroxyurea have been mentioned in the context of this disorder.

Related Diseases for Sickle Cell - Hemoglobin D Disease

Diseases related to Sickle Cell - Hemoglobin D Disease via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 hemoglobin d disease 10.1
2 acute chest syndrome 9.8

Symptoms & Phenotypes for Sickle Cell - Hemoglobin D Disease

Drugs & Therapeutics for Sickle Cell - Hemoglobin D Disease

Drugs for Sickle Cell - Hemoglobin D Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 3 7439-89-6 23925
2
Hydroxyurea Approved Phase 3,Phase 2,Phase 1,Early Phase 1 127-07-1 3657
3
Deferasirox Approved, Investigational Phase 3 201530-41-8 5493381
4 Trace Elements Phase 3,Phase 2
5 Micronutrients Phase 3,Phase 2
6 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
7 Chelating Agents Phase 3
8 Iron Chelating Agents Phase 3
9 Liver Extracts Phase 3
10
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
11
Simvastatin Approved Phase 1, Phase 2 79902-63-9 54454
12
Propranolol Approved, Investigational Phase 2 525-66-6 4946
13
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
14
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
15
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
16
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
17
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
18
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
19
Busulfan Approved, Investigational Phase 2 55-98-1 2478
20
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
21
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
22
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
23
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
24
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
25
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
26
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
27
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
28
Cholecalciferol Approved, Nutraceutical Phase 2 67-97-0 6221 10883523 5280795
29
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
30 vitamin d Phase 2
31 Hemostatics Phase 2
32 Ergocalciferols Phase 2
33 Vitamins Phase 2
34 Bone Density Conservation Agents Phase 2
35 Calcium, Dietary Phase 2,Phase 1
36 Adrenergic Agents Phase 2
37 Adrenergic Antagonists Phase 2
38 Neurotransmitter Agents Phase 2,Phase 1
39 Adrenergic beta-Antagonists Phase 2
40 Nitric Oxide Donors Phase 1, Phase 2
41 Histone Deacetylase Inhibitors Phase 2
42 Peripheral Nervous System Agents Phase 2,Phase 1
43 Vasodilator Agents Phase 2,Phase 1
44 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2
45 Anti-Arrhythmia Agents Phase 2
46 Hypolipidemic Agents Phase 1, Phase 2
47 Immunoglobulins Phase 2
48 Antibodies, Monoclonal Phase 2
49 Anticholesteremic Agents Phase 1, Phase 2
50 Protective Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 Novel Use Of Hydroxyurea in an African Region With Malaria Active, not recruiting NCT01976416 Phase 3
2 Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas Not yet recruiting NCT03128515 Phase 3
3 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3
4 Vitamin D for Sickle Cell Unknown status NCT01331148 Phase 2
5 A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) Unknown status NCT01202812 Phase 2
6 Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease Completed NCT01000155 Phase 2
7 Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease Completed NCT00842088 Phase 1, Phase 2
8 Decitabine for High-Risk Sickle Cell Disease Completed NCT01375608 Phase 2
9 Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia Completed NCT00001197 Phase 2
10 Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) Completed NCT01077921 Phase 2
11 Simvastatin (Zocor) Therapy in Sickle Cell Disease Completed NCT00508027 Phase 1, Phase 2
12 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises Completed NCT01895361 Phase 2
13 Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease Recruiting NCT03077542 Phase 1, Phase 2
14 Stem Cell Transplant in Sickle Cell Disease and Thalassemia Recruiting NCT00408447 Phase 2
15 Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia Active, not recruiting NCT00977691 Phase 1, Phase 2
16 A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease Enrolling by invitation NCT01800526 Phase 1, Phase 2
17 Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Terminated NCT00034528 Phase 2
18 A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension Withdrawn NCT00850369 Phase 2
19 Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis Withdrawn NCT01932554 Phase 2
20 Far Infrared Radiation for Sickle Cell Pain Management Unknown status NCT00599482 Phase 1
21 Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia Completed NCT00270478 Phase 1
22 Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease Completed NCT00072826 Phase 1
23 Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease Completed NCT00095472 Phase 1
24 Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia Completed NCT00056433 Phase 1
25 Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension Completed NCT00023296 Phase 1
26 A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered Recruiting NCT03126695 Phase 1
27 Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease Completed NCT02394431
28 Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease Completed NCT02225145
29 Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria Completed NCT00367523
30 Long Term Effects of Erythrocyte Lysis Completed NCT00842621
31 Adherence to Hydroxyurea in Children With Sickle Cell Anemia Completed NCT00672789
32 Evaluation of Toxicity From Stem Cell Transplant Completed NCT00631787
33 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease Recruiting NCT02225132 Early Phase 1
34 Sickle Cell Hemoglobinopathies and Bone Health Recruiting NCT02306993
35 Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease Recruiting NCT00012545
36 Cerebrovascular Reserve Measurements in Sickle Cell Disease Recruiting NCT02824406
37 Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell Recruiting NCT02561312
38 Natural History of Sickle Cell Disease Recruiting NCT00081523
39 Screening for Subjects to Participate in Studies of Blood Disorders Recruiting NCT00695123
40 Sickle Cell Disease Biofluid Chip Technology (SCD BioChip) Recruiting NCT02824471
41 Vitamin D and Bisphosphonates in the Treatment of Sickle Cell Disease Active, not recruiting NCT02972138
42 Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care Not yet recruiting NCT03167450

Search NIH Clinical Center for Sickle Cell - Hemoglobin D Disease

Genetic Tests for Sickle Cell - Hemoglobin D Disease

Genetic tests related to Sickle Cell - Hemoglobin D Disease:

id Genetic test Affiliating Genes
1 Sickle Cell-Hemoglobin D Disease 29

Anatomical Context for Sickle Cell - Hemoglobin D Disease

Publications for Sickle Cell - Hemoglobin D Disease

Articles related to Sickle Cell - Hemoglobin D Disease:

id Title Authors Year
1
Pulmonary thromboembolism in a child with sickle cell hemoglobin d disease in the setting of acute chest syndrome. ( 24159402 )
2013
2
First report of successful stem cell transplantation in a patient with sickle cell hemoglobin D disease. ( 20502357 )
2010
3
Sickle cell hemoglobin D disease: first reported case in Iran. ( 754514 )
1978
4
SICKLE CELL HEMOGLOBIN D DISEASE IN A NEGRO COLOMBIAN PATIENT. ( 14295513 )
1965

Variations for Sickle Cell - Hemoglobin D Disease

Expression for Sickle Cell - Hemoglobin D Disease

Search GEO for disease gene expression data for Sickle Cell - Hemoglobin D Disease.

Pathways for Sickle Cell - Hemoglobin D Disease

GO Terms for Sickle Cell - Hemoglobin D Disease

Sources for Sickle Cell - Hemoglobin D Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....